Remove Presentation Remove Small Molecule Remove Therapies
article thumbnail

How GPCR-targeting therapies are advancing the fight against inflammatory disease

Drug Target Review

In this article, Stephan Schann, Chief Scientific Officer at Domain Therapeutics , explains why this class of drug target is so useful despite the challenges they present. GPCR-targeting therapies such as DT-9046 represent a compelling opportunity in that respect, with major clinical and commercial potential.

Disease 59
article thumbnail

How to find a drug: the past, present and future of small molecule drug discovery?

DrugBaron

Despite the current hype around so called “advanced therapies”, which range from gene editing to cell therapies, and the inexorable advance of biologic therapeutics such as monoclonal antibodies, even in 2022 the majority of drugs in development and reaching patients are still small organic molecules.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

How GPCR agonists, including antibodies, are shaping the future of metabolic care

Drug Target Review

Confo Therapeutics , led by CEO Dr Cedric Ververken, is at the forefront of developing innovative GPCR-targeted therapies using its proprietary ConfoBody ® platform. In addition to generating agonistic antibodies, Confo is also successfully applying the ConfoBody/ConfoChimer technology to drugging GPCR with small molecules.

article thumbnail

Supramolecular nanostructures for the delivery of peptides in cancer therapy [Minireview]

ASPET

The self-assembled structures can be small molecules, polymers, peptides, proteins, which can be utilized and functionalized to achieve tailored release and target specific cells, tissues, or organs. Different SNs approaches and recent literature reviews on peptide delivery are also presented to the readers.

Therapies 100
article thumbnail

Altasciences At CPHI Americas 2025

Alta Sciences

Our presentation highlighted spray drying , a powerful technique that can turn liquid formulations into fine powders. Because this transformation can significantly improve the stability, solubility, and overall performance of pharmaceutical compounds, especially when it comes to small molecules. Why does that matter?

article thumbnail

Bristol Myers Squibb Highlights Targeted Protein Degradation Data, Including CELMoD Agents, at EHA 2025

The Pharma Data

The presentations highlight the ongoing progress and growing promise of the company’s innovative therapeutic platform, featuring its investigational oral CELMoD™ (Cereblon E3 Ligase Modulating Drugs) agents mezigdomide, iberdomide, and golcadomide, alongside its first-in-class, oral BCL6 (B-Cell lymphoma 6) ligand-directed degrader (LDD) BMS-986458.

article thumbnail

The rising impact of biomarkers in early clinical development

Drug Target Review

As our understanding of the underlying biology of disease grows more sophisticated, emerging therapies operate on increasingly complex biopathological systems and mechanisms. Safety biomarkers account for adverse effects of a therapy under study. There are several types of biomarkers to consider.